The discovery of this YBX1/tRF-GlyTCC/RUNX2 interaction led to the development and testing of the RUNX2 transcription factor and ATP synthase inhibitor CADD522 [45], [46] as a novel single agent PBC treatment without surgery in vivo. The gene discussed is YBX1; the disease is primary biliary cholangitis.